Charles River Laboratories International, Inc. (CRL)
CRL Q1 Earnings & Revenues Top Estimates, Margins Crash, Stock Down
Charles River beats Q1 earnings and revenue estimates, but margin declines and weak organic growth in key segments send shares lower in pre-market.
Compared to Estimates, Charles River (CRL) Q1 Earnings: A Look at Key Metrics
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Charles River Laboratories (CRL) Surpasses Q1 Earnings and Revenue Estimates
Charles River Laboratories (CRL) came out with quarterly earnings of $2.06 per share, beating the Zacks Consensus Estimate of $1.96 per share. This compares to earnings of $2.34 per share a year ago.
Charles River (CRL) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Evaluate the expected performance of Charles River (CRL) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Charles River Laboratories (CRL) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Is Charles River (CRL) Down 6.8% Since Last Earnings Report?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
Algert Global LLC Buys 39,586 Shares of Charles River Laboratories International, Inc. $CRL
Algert Global LLC increased its stake in Charles River Laboratories International, Inc. (NYSE: CRL) by 54.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 112,870 shares of the medical research company's stock after purchasing an additional 39,586 shares during
Charles River Laboratories International, Inc. (CRL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
